FHND5071

FHND5071 is a potent and selective small molecule inhibitor of the RET (rearranged during transfection) receptor tyrosine kinase. It acts by selectively targeting and binding to wild-type RET as well as various RET fusions and mutations, thereby inhibiting RET autophosphorylation and downstream signaling. This inhibition leads to reduced cell growth in tumors with increased RET activity due to these genetic alterations[1][2][3][4][7]. FHND5071 has demonstrated significant antitumor efficacy in preclinical models, including those with CCDC6-RET or NCOA4-RET fusions, showing tumor growth inhibition and prolonged survival in intracranial xenograft models[5]. The drug is characterized by favorable pharmacokinetic properties such as long in vivo efficacy, high tumor tissue distribution rate, low effective dose, ability to cross the blood-brain barrier, moderate absorption (bioavailability >60%), rapid tissue distribution (peaking at 1–4 hours), and wide organ exposure[4][7]. FHND5071 is being developed primarily for advanced solid tumors harboring RET alterations.